risedronic acid has been researched along with cholecalciferol in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, S | 1 |
| Cobaleda, B; Gómez-Juaristi, M; González, EM; Guadalix, S; Hawkins, F; Lora, D; Martínez-Díaz-Guerra, G; Vargas, C | 1 |
| Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK | 1 |
| Chang, JS; Chung, HY; Chung, YS; Kang, MI; Koo, J; Kwon, SK; Moon, SH; Park, HM; Park, JY; Shin, CS; Yoon, BK; Yoon, HK | 1 |
| Biamonte, F; Biondi, P; Cipriani, C; Del Fiacco, R; Diacinti, D; Falciano, M; Iaiani, G; Isidori, AM; Lenzi, A; Minisola, S; Pepe, J; Piemonte, S; Raimo, O; Salotti, A; Sbardella, E | 1 |
| Babinets', LS; Borovyk, IO; Semenova, IV | 1 |
| Cadarette, SM; Jandoc, R; Lévesque, LE; Mamdani, M | 1 |
| Bouillon, R; De Clercq, P; Doms, S; Janssens, I; Vanhevel, J; Verlinden, L; Verstuyf, A | 1 |
| Chang, JS; Choi, H; Chung, HY; Kang, MI; Kim, IJ; Koh, JM; Moon, SH; Park, HM; Park, SY; Park, YS; Rhee, Y; Shin, CS; Won, YY; Yoon, HK; Yoon, TR; Yun, SC | 1 |
1 review(s) available for risedronic acid and cholecalciferol
| Article | Year |
|---|---|
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence-Based Medicine; Glucocorticoids; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Vitamin K 2 | 2007 |
4 trial(s) available for risedronic acid and cholecalciferol
| Article | Year |
|---|---|
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cholecalciferol; Etidronic Acid; Female; Humans; Liver Transplantation; Male; Middle Aged; Postmenopause; Prospective Studies; Risedronic Acid; Spinal Fractures | 2011 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Korea; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prospective Studies; Radioimmunoassay; Risedronic Acid; Treatment Outcome; Vitamin D | 2011 |
Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Chi-Square Distribution; Cholecalciferol; Collagen Type I; Double-Blind Method; Drug Combinations; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Republic of Korea; Risedronic Acid; Treatment Outcome; Vitamin D | 2013 |
Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Drug Administration Schedule; Drug Therapy, Combination; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Parathyroid Hormone; Pelvic Bones; Prospective Studies; Republic of Korea; Risedronic Acid; Treatment Outcome; Vitamin D | 2019 |
5 other study(ies) available for risedronic acid and cholecalciferol
| Article | Year |
|---|---|
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Time Factors | 2009 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; HIV Infections; Humans; Hypogonadism; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Pilot Projects; Risedronic Acid; Testosterone; Treatment Outcome | 2014 |
[Osteodeficiency in chronic pancreatitis: ways of correction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Calcium Carbonate; Cholecalciferol; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Pancreatitis, Chronic; Risedronic Acid | 2014 |
Urban-rural differences in the uptake of new oral bisphosphonate formulations.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Female; Humans; Male; Ontario; Osteoporosis; Patient Acceptance of Health Care; Risedronic Acid; Rural Health; Urban Health | 2016 |
WY 1048, a 17-methyl 19-nor D-ring analog of vitamin D
Topics: Animals; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Disease Models, Animal; Female; Humans; Mice; Osteoporosis, Postmenopausal; Risedronic Acid; Vitamins | 2019 |